Back to School: How biopharma can reboot drug development. Access exclusive analysis here

InSite, Merck deal

InSite regained North American development rights to AzaSite Xtra 2% azithromycin ophthalmic solution from Inspire Pharmaceuticals

Read the full 166 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE